Kris Cameron Wood

Image of Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information:

  • Email Address: kris.wood@duke.edu
  • Web Page:

Education:

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky, Lexington, 2002

Courses Taught:

  • BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
  • BIOLOGY 728E: University Program in Genetics and Genomics Biological Solutions Module V
  • CMB 710D: Cell & Molecular Biology Module IV
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • CMB 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MGM 778E: University Program in Genetics and Genomics Biological Solutions Module V
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • UPGEN 778E: University Program in Genetics and Genomics Biological Solutions Module V

Representative Publications:

  • Su, A; Ling, F; Vaganay, C; Sodaro, G; Benaksas, C; Dal Bello, R; Forget, A; Pardieu, B; Lin, KH; Rutter, JC; Bassil, CF; Fortin, G; Pasanisi, J; Antony-Debre, I; Alexe, G; Benoist, J-F; Pruvost, A; Pikman, Y; Qi, J; Schlageter, M-H; Micol, J-B; Roti, G; Cluzeau, T; Dombret, H; Preudhomme, C; Fenouille, N; Benajiba, L; Golan, HM; Stegmaier, K; Lobry, C; Wood, KC; Itzykson, R; Puissant, A, The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies., Cancer Discov (2020) [10.1158/2159-8290.CD-19-0970] [abs].
  • Ozkan-Dagliyan, I; Diehl, JN; George, SD; Schaefer, A; Papke, B; Klotz-Noack, K; Waters, AM; Goodwin, CM; Gautam, P; Pierobon, M; Peng, S; Gilbert, TSK; Lin, KH; Dagliyan, O; Wennerberg, K; Petricoin, EF; Tran, NL; Bhagwat, SV; Tiu, RV; Peng, S-B; Herring, LE; Graves, LM; Sers, C; Wood, KC; Cox, AD; Der, CJ, Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers., Cell Reports, vol 31 no. 11 (2020) [10.1016/j.celrep.2020.107764] [abs].
  • Lin, KH; Rutter, JC; Xie, A; Pardieu, B; Winn, ET; Bello, RD; Forget, A; Itzykson, R; Ahn, Y-R; Dai, Z; Sobhan, RT; Anderson, GR; Singleton, KR; Decker, AE; Winter, PS; Locasale, JW; Crawford, L; Puissant, A; Wood, KC, Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer., Nat Genet, vol 52 no. 4 (2020), pp. 408-417 [10.1038/s41588-020-0590-9] [abs].
  • Wood, KC, Druggable Vulnerabilities in Therapy-Resistant Lung Cancers, Journal of Thoracic Oncology, vol 15 no. 2 (2020), pp. S6-S6 [abs].
  • Wood, KC, Overcoming MCL-1-driven adaptive resistance to targeted therapies., Nature Communications, vol 11 no. 1 (2020) [10.1038/s41467-020-14392-z] [abs].